ATE496021T1 - Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen - Google Patents

Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen

Info

Publication number: ATE496021T1
Authority: AT; Austria
Prior art keywords: methylpropyl; dimethylamino; ethyl; active ingredients; pharmaceutical preparations
Prior art date: 2004-06-28

Application number

AT05770026T

Other languages

English (en)

Inventor

Andreas Fischer

Helmut Buschmann

Michael Gruss

Dagmar Lischke

Original Assignee

Gruenenthal Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-28

Filing date

2005-06-27

Publication date

2011-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496021(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-27 Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE496021T1 publication Critical patent/ATE496021T1/de

Links

ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT05770026T 2004-06-28 2005-06-27 Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen ATE496021T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04015091A EP1612203B1 (de)	2004-06-28	2004-06-28	Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
PCT/EP2005/006884 WO2006000441A2 (en)	2004-06-28	2005-06-27	Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number	Publication Date
ATE496021T1 true ATE496021T1 (de)	2011-02-15

Family

ID=34925507

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04015091T ATE368639T1 (de)	2004-06-28	2004-06-28	Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
AT05770026T ATE496021T1 (de)	2004-06-28	2005-06-27	Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04015091T ATE368639T1 (de)	2004-06-28	2004-06-28	Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid

Country Status (27)

Country	Link
US (16)	US20070213405A1 (de)
EP (2)	EP1612203B1 (de)
JP (1)	JP4990764B2 (de)
KR (1)	KR101096501B1 (de)
CN (1)	CN1997621B (de)
AR (2)	AR049949A1 (de)
AT (2)	ATE368639T1 (de)
AU (1)	AU2005256512B2 (de)
BR (2)	BRPI0512792A (de)
CA (1)	CA2572147C (de)
CY (2)	CY1106929T1 (de)
DE (2)	DE602004007905T2 (de)
DK (2)	DK1612203T3 (de)
EC (1)	ECSP17046065A (de)
ES (2)	ES2291780T3 (de)
HR (1)	HRP20110050T8 (de)
IL (1)	IL180373A (de)
MX (1)	MXPA06014741A (de)
NO (3)	NO338605B1 (de)
NZ (1)	NZ551605A (de)
PE (1)	PE20060372A1 (de)
PL (2)	PL1612203T3 (de)
PT (2)	PT1612203E (de)
RU (1)	RU2423345C2 (de)
SI (2)	SI1612203T1 (de)
WO (1)	WO2006000441A2 (de)
ZA (1)	ZA200700774B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
SI1612203T1 (sl) *	2004-06-28	2007-12-31	Gruenenthal Chemie	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de)	2007-03-07	2008-09-11	Grünenthal GmbH	Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) *	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol zur Schmerzbehandlung bei Arthrose
SI3173400T1 (sl) *	2007-12-07	2020-01-31	Gruenenthal Gmbh	Zdravila, ki vsebujejo kristalinične modifikacije (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
JP5774853B2 (ja)	2008-01-25	2015-09-09	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	医薬投薬形
MX2010012039A (es)	2008-05-09	2010-11-30	Gruenenthal Gmbh	Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
US20100272815A1 (en) *	2009-04-28	2010-10-28	Actavis Group Ptc Ehf	Amorphous form of tapentadol hydrochloride
BR112012001547A2 (pt)	2009-07-22	2016-03-08	Gruenenthal Gmbh	forma de dosagem farmacêutica extrusada por fusão a quente
ES2428938T3 (es)	2009-07-22	2013-11-12	Grünenthal GmbH	Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
US8288592B2 (en)	2009-09-22	2012-10-16	Actavis Group Ptc Ehf	Solid state forms of tapentadol salts
US20130116333A1 (en)	2010-05-05	2013-05-09	Ratiopharm Gmbh	Solid tapentadol in non-crystalline form
LT3656765T (lt)	2010-07-23	2021-06-10	Grünenthal GmbH	3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio druskos arba bendri kristalai
CN103179954A (zh)	2010-09-02	2013-06-26	格吕伦塔尔有限公司	包含阴离子聚合物的抗破碎剂型
CA2808219C (en)	2010-09-02	2019-05-14	Gruenenthal Gmbh	Tamper resistant dosage form comprising inorganic salt
WO2012051246A1 (en)	2010-10-12	2012-04-19	Ratiopharm Gmbh	Tapentadol hydrobromide and crystalline forms thereof
MX374468B (es)	2011-03-04	2025-03-06	Gruenenthal Gmbh	Composicion farmaceutica acuosa semisolida que contiene tapentadol.
MX369121B (es)	2011-03-04	2019-10-30	Gruenenthal Gmbh	Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EA024193B1 (ru) *	2011-03-04	2016-08-31	Грюненталь Гмбх	Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
CA2839123A1 (en)	2011-07-29	2013-02-07	Grunenthal Gmbh	Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl)	2011-07-29	2018-01-31	Gruenenthal Gmbh	Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
WO2013111161A2 (en) *	2012-01-10	2013-08-01	Msn Laboratories Limited	Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en)	2012-02-17	2013-08-22	Zentiva, K.S.	A new solid form of tapentadol and a method of its preparation
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl)	2012-04-18	2018-12-31	Grünenthal GmbH	Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) *	2012-07-24	2014-07-16	Zentiva, K.S.	Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) *	2012-10-31	2013-11-20	合肥市新星医药化工有限公司	盐酸他喷他多晶型c及其制备方法和应用
WO2014191396A1 (en)	2013-05-29	2014-12-04	Grünenthal GmbH	Tamper resistant dosage form with bimodal release profile
MX371432B (es)	2013-05-29	2020-01-30	Gruenenthal Gmbh	Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
EP2808319A1 (de)	2013-05-31	2014-12-03	Arevipharma GmbH	3-[3-(dimethylamin)-1-ethyl-2-methylpropyl]phenolharzkomplex
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (de) *	2013-09-04	2015-03-11	Grünenthal GmbH	Tepentadol zur Verwendung bei der Behandlung von Fibromyalgie und chronischem Ermüdungssyndrom
USD730877S1 (en)	2013-09-06	2015-06-02	Plantronics, Inc.	Communications headset
US9599565B1 (en) *	2013-10-02	2017-03-21	Ondax, Inc.	Identification and analysis of materials and molecular structures
WO2015071248A1 (en)	2013-11-15	2015-05-21	Synthon B.V.	Abuse-proofed extended release pharmaceutical composition comprising tapentadol
WO2015078891A1 (en)	2013-11-26	2015-06-04	Farmaceutici Formenti S.P.A.	Preparation of a powdery pharmaceutical composition by means of cryo-milling
CZ307492B6 (cs)	2014-02-04	2018-10-17	Zentiva, K.S.	Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) *	2014-02-12	2015-08-19	Azad Pharmaceutical Ingredients Ag	Stable polymorph form B of tapentadol hydrochloride
US20150320690A1 (en)	2014-05-12	2015-11-12	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de)	2014-05-26	2017-04-05	Grünenthal GmbH	Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
EA036258B1 (ru)	2015-03-27	2020-10-20	Грюненталь Гмбх	Стабильный препарат для парентерального введения тапентадола
BR112017021475A2 (pt)	2015-04-24	2018-07-10	Gruenenthal Gmbh	forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en)	2015-09-10	2018-02-22	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2017182438A1 (en)	2016-04-19	2017-10-26	Ratiopharm Gmbh	Crystalline tapentadol phosphate
CN109996533A (zh)	2016-09-23	2019-07-09	格吕伦塔尔有限公司	用于肠胃外施用他喷他多的稳定制剂
EP3585370A1 (de)	2017-02-23	2020-01-01	Grünenthal GmbH	Tapentadol als lokalanästhetikum
CA3196954A1 (en)	2020-11-03	2022-05-12	Josep Bassaganya-Riera	Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4426245A1 (de) *	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
BR9711151A (pt) *	1996-08-14	1999-08-17	Searle & Co	Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
PL361912A1 (en) *	2000-10-31	2004-10-04	Ciba Specialty Chemicals Holding Inc.	Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) *	2001-02-28	2005-08-11	Johannes Bartholomaus	Pharmaceutical salts
US7208520B2 (en) *	2001-09-13	2007-04-24	Kissei Pharmaceutical Co., Ltd.	Crystals of hydroxynorephedrine derivative
PE20030527A1 (es) *	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
SI1612203T1 (sl) *	2004-06-28	2007-12-31	Gruenenthal Chemie	Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
SI3173400T1 (sl) *	2007-12-07	2020-01-31	Gruenenthal Gmbh	Zdravila, ki vsebujejo kristalinične modifikacije (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola

2004
- 2004-06-28 SI SI200430461T patent/SI1612203T1/sl unknown
- 2004-06-28 AT AT04015091T patent/ATE368639T1/de active
- 2004-06-28 DE DE602004007905T patent/DE602004007905T2/de not_active Expired - Lifetime
- 2004-06-28 DK DK04015091T patent/DK1612203T3/da active
- 2004-06-28 PT PT04015091T patent/PT1612203E/pt unknown
- 2004-06-28 EP EP04015091A patent/EP1612203B1/de not_active Expired - Lifetime
- 2004-06-28 PL PL04015091T patent/PL1612203T3/pl unknown
- 2004-06-28 ES ES04015091T patent/ES2291780T3/es not_active Expired - Lifetime
2005
- 2005-06-27 KR KR1020077002099A patent/KR101096501B1/ko not_active Expired - Lifetime
- 2005-06-27 NZ NZ551605A patent/NZ551605A/en not_active IP Right Cessation
- 2005-06-27 DK DK05770026.2T patent/DK1799633T3/da active
- 2005-06-27 PL PL05770026T patent/PL1799633T3/pl unknown
- 2005-06-27 RU RU2007103297/04A patent/RU2423345C2/ru active
- 2005-06-27 AU AU2005256512A patent/AU2005256512B2/en not_active Expired
- 2005-06-27 HR HR20110050T patent/HRP20110050T8/xx unknown
- 2005-06-27 MX MXPA06014741A patent/MXPA06014741A/es active IP Right Grant
- 2005-06-27 PE PE2005000742A patent/PE20060372A1/es active IP Right Grant
- 2005-06-27 EP EP05770026A patent/EP1799633B1/de not_active Expired - Lifetime
- 2005-06-27 DE DE602005026031T patent/DE602005026031D1/de not_active Expired - Lifetime
- 2005-06-27 AT AT05770026T patent/ATE496021T1/de active
- 2005-06-27 PT PT05770026T patent/PT1799633E/pt unknown
- 2005-06-27 JP JP2007518520A patent/JP4990764B2/ja not_active Expired - Lifetime
- 2005-06-27 CA CA2572147A patent/CA2572147C/en not_active Expired - Lifetime
- 2005-06-27 SI SI200531252T patent/SI1799633T1/sl unknown
- 2005-06-27 CN CN2005800216611A patent/CN1997621B/zh not_active Expired - Fee Related
- 2005-06-27 BR BRPI0512792-0A patent/BRPI0512792A/pt not_active Application Discontinuation
- 2005-06-27 WO PCT/EP2005/006884 patent/WO2006000441A2/en not_active Ceased
- 2005-06-27 BR BR122018014454A patent/BR122018014454B8/pt active IP Right Grant
- 2005-06-27 ES ES05770026T patent/ES2359504T3/es not_active Expired - Lifetime
- 2005-06-28 AR ARP050102663A patent/AR049949A1/es not_active Application Discontinuation
2006
- 2006-12-26 IL IL180373A patent/IL180373A/en active IP Right Grant
- 2006-12-28 US US11/646,232 patent/US20070213405A1/en not_active Abandoned
2007
- 2007-01-09 NO NO20070162A patent/NO338605B1/no unknown
- 2007-01-26 ZA ZA200700774A patent/ZA200700774B/xx unknown
- 2007-10-11 CY CY20071101312T patent/CY1106929T1/el unknown
2008
- 2008-11-20 US US12/274,747 patent/US20090186947A1/en not_active Abandoned
2009
- 2009-12-10 US US12/634,777 patent/US7994364B2/en not_active Expired - Lifetime
2011
- 2011-02-16 CY CY20111100192T patent/CY1111530T1/el unknown
- 2011-06-29 US US13/172,009 patent/US20110294898A1/en not_active Abandoned
2012
- 2012-08-03 US US13/565,867 patent/US20120302643A1/en not_active Abandoned
2013
- 2013-06-21 US US13/923,891 patent/US20140011886A1/en not_active Abandoned
2014
- 2014-06-13 US US14/304,313 patent/US20140296346A1/en not_active Abandoned
2015
- 2015-11-02 US US14/930,337 patent/US20160122287A1/en not_active Abandoned
2016
- 2016-05-30 NO NO20160914A patent/NO341239B1/no unknown
2017
- 2017-02-09 US US15/428,613 patent/US20170166515A1/en not_active Abandoned
- 2017-07-04 NO NO20171103A patent/NO343922B1/no unknown
- 2017-07-17 EC ECIEPI201746065A patent/ECSP17046065A/es unknown
- 2017-10-05 US US15/725,967 patent/US20180029976A1/en not_active Abandoned
2018
- 2018-04-12 US US15/951,838 patent/US20180230082A1/en not_active Abandoned
- 2018-10-26 US US16/172,100 patent/US20190062263A1/en not_active Abandoned
2019
- 2019-09-02 AR ARP190102495A patent/AR116052A2/es not_active Application Discontinuation
- 2019-10-14 US US16/600,884 patent/US20200102261A1/en not_active Abandoned
2020
- 2020-06-23 US US16/909,123 patent/US20200385334A1/en not_active Abandoned
2021
- 2021-03-08 US US17/194,717 patent/US20210261492A1/en not_active Abandoned
2023
- 2023-01-30 US US18/103,410 patent/US20230174458A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20120302643A1 (en)	2012-11-29
EP1799633A2 (de)	2007-06-27
US7994364B2 (en)	2011-08-09
US20180230082A1 (en)	2018-08-16
HRP20110050T1 (hr)	2011-02-28
PL1612203T3 (pl)	2007-12-31
ZA200700774B (en)	2008-09-25
MXPA06014741A (es)	2007-02-12
DE602004007905D1 (de)	2007-09-13
US20160122287A1 (en)	2016-05-05
CN1997621A (zh)	2007-07-11
DK1612203T3 (da)	2007-12-03
PL1799633T3 (pl)	2011-06-30
CY1111530T1 (el)	2015-08-05
BRPI0512792A (pt)	2008-04-08
US20230174458A1 (en)	2023-06-08
AU2005256512B2 (en)	2011-05-19
US20090186947A1 (en)	2009-07-23
CN1997621B (zh)	2011-06-15
PT1612203E (pt)	2007-08-20
ES2291780T3 (es)	2008-03-01
US20190062263A1 (en)	2019-02-28
CA2572147A1 (en)	2006-01-05
BR122018014454B1 (pt)	2019-09-03
NO343922B1 (no)	2019-07-08
HRP20110050T8 (en)	2011-03-31
IL180373A0 (en)	2007-06-03
IL180373A (en)	2012-05-31
US20140011886A1 (en)	2014-01-09
NZ551605A (en)	2010-01-29
DK1799633T3 (da)	2011-03-28
US20110294898A1 (en)	2011-12-01
US20210261492A1 (en)	2021-08-26
AR116052A2 (es)	2021-03-25
AR049949A1 (es)	2006-09-20
RU2007103297A (ru)	2008-08-10
BR122018014454B8 (pt)	2021-07-27
SI1612203T1 (sl)	2007-12-31
ATE368639T1 (de)	2007-08-15
NO20070162L (no)	2007-01-24
EP1799633B1 (de)	2011-01-19
NO341239B1 (no)	2017-09-25
US20200102261A1 (en)	2020-04-02
AU2005256512A1 (en)	2006-01-05
DE602005026031D1 (de)	2011-03-03
RU2423345C2 (ru)	2011-07-10
JP2008504326A (ja)	2008-02-14
EP1612203B1 (de)	2007-08-01
ES2359504T3 (es)	2011-05-24
CY1106929T1 (el)	2012-09-26
US20200385334A1 (en)	2020-12-10
ECSP17046065A (es)	2018-11-30
US20100160447A1 (en)	2010-06-24
WO2006000441A3 (en)	2006-05-04
US20140296346A1 (en)	2014-10-02
US20180029976A1 (en)	2018-02-01
EP1612203A1 (de)	2006-01-04
JP4990764B2 (ja)	2012-08-01
KR20070039929A (ko)	2007-04-13
NO20160914A1 (no)	2007-01-24
US20070213405A1 (en)	2007-09-13
SI1799633T1 (sl)	2011-05-31
NO20171103A1 (no)	2007-01-24
NO338605B1 (no)	2016-09-12
PT1799633E (pt)	2011-03-07
US20170166515A1 (en)	2017-06-15
WO2006000441A2 (en)	2006-01-05
PE20060372A1 (es)	2006-05-08
DE602004007905T2 (de)	2008-05-08
CA2572147C (en)	2012-10-30
KR101096501B1 (ko)	2011-12-20

Legal Events

Date

Code

Title

Description

2011-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1799633

Country of ref document: EP

Publication	Publication Date	Title
ATE496021T1 (de)	2011-02-15	Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
EA200970532A1 (ru)	2009-10-30	Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EA200602137A1 (ru)	2007-04-27	Гидрогелевые препараты интерферона
ZA200705750B (en)	2008-11-26	Compositions and methods for stabilizing active pharmaceutical ingredients
EA201300121A1 (ru)	2014-12-30	Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
ATE470443T1 (de)	2010-06-15	Indol-1-yl-essigsäurederivate
ATE482213T1 (de)	2010-10-15	Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TN2010000019A1 (en)	2011-09-26	Solid preparation comprising alogliptin and metformin hydrochloride
EA200501586A1 (ru)	2006-04-28	Фармацевтические продукты
NI201200072A (es)	2012-08-20	Métodos y composiciones para tratar cáncer
BR112012006252A2 (pt)	2017-05-23	"formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
ECSP10010265A (es)	2010-07-30	Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
EP2343080A4 (de)	2012-10-03	Pharmazeutische zusammensetzung zur behandlung von knochenerkrankungen mit einem protein mit extrazellulären zysteinreichen frizzled1-, frizzled2- oder frizzled7-domänen
FR2850576B1 (fr)	2007-03-23	Composition comprenant un melange de principes actifs, et procede de preparation
ECSP055701A (es)	2005-05-30	Nuevos derivados de pirimidinamida y el uso de los mismos
EA200401515A1 (ru)	2005-06-30	Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
ATE383854T1 (de)	2008-02-15	Kombination ausgewählter opioide mit muscarin- antagonisten zur therapie der harninkontinenz
EA200602092A1 (ru)	2007-06-29	Способ и композиция для лечения ринита
ATE385786T1 (de)	2008-03-15	Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen
WO2005004894A3 (en)	2005-03-31	Methods for increasing cell and tissue viability
EA200801614A1 (ru)	2008-10-30	Фармацевтическая композиция, содержащая монтелукаст
SG165397A1 (en)	2010-10-28	Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
EA200701072A1 (ru)	2007-10-26	Препараты бензотиазола и их применение
FR2868704B1 (fr)	2007-09-14	Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
ATE549404T1 (de)	2012-03-15	Verfahren zum screening eines transmembranenzymhemmstoffs